Literature DB >> 14885177

The effect of antibiotics (penicillin, aureomycin, and terramycin) on the fatality rate and incidence of complications in pneumococcic pneumonia; a comparison with other methods of therapy.

H F DOWLING, M H LEPPER.   

Abstract

Entities:  

Keywords:  ANTIBIOTICS/therapeutic use; PNEUMOCOCCAL INFECTIONS/therapy; PNEUMONIA/therapy; SULFONAMIDES/therapeutic use

Mesh：

Substances：

Year:  1951        PMID： 14885177     DOI： 10.1097/00000441-195110000-00005

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN： 0002-9629            Impact factor:   2.378


× No keyword cloud information.
  10 in total

1.  [Chemotherapy of non-tuberculous pulmonary infections].

Authors:  C H STUART-HARRIS
Journal:  Br Med J       Date:  1959-06-27

2.  Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia.

Authors:  Brad Spellberg; Roger J Lewis; Helen W Boucher; Eric P Brass
Journal:  Clin Investig (Lond)       Date:  2011-01-01

3.  Antibiotic therapy of cholera.

Authors:  J Lindenbaum; W B Greenough; M R Islam
Journal:  Bull World Health Organ       Date:  1967       Impact factor: 9.408

Review 4.  Issues in noninferiority trials: the evidence in community-acquired pneumonia.

Authors:  Thomas R Fleming; John H Powers
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

5.  Community-acquired pneumonia of diverse aetiology: prognostic features in patients admitted to an intensive care unit and a "severity of illness" core.

Authors:  C Feldman; J M Kallenbach; H Levy; S G Reinach; M D Hurwitz; J R Thorburn; H J Koornhof
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

Review 6.  Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.

Authors:  Brad Spellberg; George H Talbot; Eric P Brass; John S Bradley; Helen W Boucher; David N Gilbert
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

7.  Induction of pro- and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza.

Authors:  Matthew W Smith; Jeffrey E Schmidt; Jerold E Rehg; Carlos J Orihuela; Jonathan A McCullers
Journal:  Comp Med       Date:  2007-02       Impact factor: 0.982

8.  Characterizing Risk Factors for Clostridioides difficile Infection among Hospitalized Patients with Community-Acquired Pneumonia.

Authors:  Caroline C Jozefczyk; W Justin Moore; Paul R Yarnold; Nathaniel J Rhodes; Karolina Harkabuz; Robert Maxwell; Sarah H Sutton; Christina Silkaitis; Chao Qi; Richard G Wunderink; Teresa R Zembower
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

9.  Lung health in a changing world.

Authors:  Matthew J Peters; Jane E Bourke
Journal:  Med J Aust       Date:  2017-11-20       Impact factor: 7.738

Review 10.  Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing.

Authors:  Natalie K Boyd; Chengwen Teng; Christopher R Frei
Journal:  Front Cell Infect Microbiol       Date:  2021-05-17       Impact factor: 5.293
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.